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Key	Points	
• Rs12041331	is	the	first	functional	CpG-SNP	related	to	platelet	function	whose	
regulatory	mechanism	depends	on	DNA	methylation	
• Rs12041331	marks	allele-specific	methylation	at	the	CpG	island	encompassing	
the	first	untranslated	exon	during	megakaryopoiesis		
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Abstract		
	
Genetic	 variation	 in	 the	PEAR1	 locus	 is	 linked	 to	platelet	 reactivity	 and	 cardiovascular	
disease.	 The	 major	 G-allele	 of	 rs12041331,	 an	 intronic	 CpG-SNP,	 is	 associated	 with	
higher	PEAR1	expression	 in	platelets	and	endothelial	cells	than	the	minor	A-allele.	The	
molecular	mechanism	underlying	this	difference	remains	elusive.	We	have	characterized	
the	 histone	 modification	 profiles	 of	 the	 intronic	 region	 surrounding	 rs12041331	 and	
identified	H3K4Me1	enhancer-specific	enrichment	 for	 the	 region	 that	 covers	 the	CpG-
SNP.	Interestingly,	methylation	studies	revealed	that	the	CpG	site	is	fully	methylated	in	
leukocytes	 of	GG	 carriers.	 Nuclear	 protein	 extracts	 from	megakaryocytes,	 endothelial	
cells	vs.	control	HEK-293	cells	show	a	3-fold	higher	affinity	for	the	methylated	G-allele,	
compared	to	non-methylated	G	or	A	alleles	 in	a	gel	EMSA.	To	understand	the	positive	
relationship	between	methylation	and	gene	expression,	we	studied	DNA	methylation	at	
4	 different	 loci	 of	 PEAR1	 during	 in	 vitro	 megakaryopoiesis.	 During	 differentiation	 the	
CpG-SNP	remained	fully	methylated,	while	we	observed	rapid	methylation	increases	at	
the	 CpG-island	 overlapping	 the	 first	 UTR	 exon,	 paralleling	 the	 increased	 PEAR1	
expression.	 In	 the	 same	 region,	 A-allele	 carriers	 of	 rs12041331	 showed	 significantly	
lower	DNA	methylation	at	CGI1	compared	to	GG	homozygote.	This	CpG-island	contains	
binding	 sites	 for	 the	methylation-sensitive	 transcription	 factor	 CTCF,	whose	 binding	 is	
known	to	play	a	role	in	enhancer	activation	and/or	repression.	In	conclusion,	we	report	
the	molecular	characterization	of	the	first	platelet	function-related	CpG-SNP,	a	genetic	
predisposition	 that	 capacitates	 PEAR1	 enhancer	 activity	 through	 allele-specific	 DNA	
methylation.	 
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Introduction	
	
PEAR1	 encodes	 the	 Platelet-endothelial	 aggregation	 receptor	 1	 (PEAR1),	 a	
transmembrane	 tyrosine	 kinase	 receptor	 predominantly	 expressed	 in	 platelets	 and	
endothelial	 cells.1	 In	 platelets,	 PEAR1	 is	 involved	 in	 cell	 activation	 through	 its	
engagement	in	sustaining	activation	of	the	platelet	integrin	αIIbβ3,2	and	platelet	FcεR1α	
has	been	identified	as	one	of	its	activating	ligands.3	PEAR1	is	progressively	more	actively	
transcribed	towards	 the	 later	stages	of	megakaryocyte	 (MK)	specification,4	 following	a	
similar	 pattern	 as	 that	 observed	 for	 GATA1.5,6	 PEAR1	 knock-down	 in	 CD34+	
hematopoietic	stem	cells	enhances	megakaryopoietic	progenitor	proliferation,4		while	in	
endothelial	cells	it	is	implicated	in	the	regulation	of	neo-angiogenesis.7		Both	processes	
occur	in	a	PI3K/PTEN-dependent	manner.		
	
Several	epidemiological	studies	have	identified	PEAR1	as	one	potential	candidate	gene	
to	explain	platelet	function	variability	both	in	healthy	and	pathological	conditions.8-19		
The	 non-coding	 PEAR1	 SNP	 rs12041331	 A-allele	 was	 associated	 with	 lower	 PEAR1	
expression9	 and	 platelet	 response	 to	 agonists	 in	 different	 reports,8,9,13,14,17,19	 while	
among	 patients	 with	 coronary	 artery	 disease	 taking	 antiplatelet	 agents,	 rs12041331	
A-allele	 carriers	 surprisingly	 appeared	 to	 experience	 more	 adverse	 cardiovascular	
outcomes	 and	 had	 higher	 death	 rates	 than	GG	 homozygotes.14	 Rs12041331	 seems	 to	
play	a	role	in	driving	endothelial	cell	function	too.20	Rs12041331	is	a	polymorphism	that	
removes	a	CpG-site	 in	 the	DNA	sequence,	and	 is	defined	as	a	“CpG-SNP”.	CpG-sites	 in	
mammals	 influence	 gene	 regulation,	 dependent	 on	 their	 methylation	 status.	 DNA	
methylation	has	been	extensively	described	 in	 the	control	of	cell	 specification,	cancer,	
and	 other	 human	 diseases21	 and	 co-operates	 with	 histone	modifications	 in	 rendering	
the	chromatin	more	or	less	accessible	for	transcription	factors,	thereby	influencing	gene	
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expression.22	Despite	reported	associations	of	CpG-SNPs	with	multiple	diseases,23-29	the	
role	of	CpG-SNPs	in	regulating	platelet	phenotypes	was	never	investigated.		
Two	studies	have	already	shown	that	PEAR1	rs12041331	G/A	substitution	leads	to	lower	
platelet	 PEAR1	 expression9	 and	 reduces	 endothelial	 cell	migration	 in	 carriers	 of	 the	A	
allele.20	 In	 this	 study	 we	 have	 addressed	 the	 transcriptional	 importance	 of	 CpG-SNP	
rs12041331	 in	 the	 context	 of	 the	PEAR1	 gene	 and	 have	 identified,	 for	 the	 first	 time,	
allele-specific	 methylation	 as	 a	 regulatory	 mechanism	 capable	 of	 modulating	 gene	
expression	 at	more	 than	 one	 level.	We	 found	 that	 this	 type	 of	 epigenetic	 regulation	
contributes	 to	 the	 fine-tuning	 of	 PEAR1	 expression	 and	 provides	 a	 molecular	
explanation	for	population	variability	in	PEAR1-dependent	platelet	function.	
	
	
Methods	
	
All	human	samples	 involved	 in	 the	study	were	obtained	 from	healthy	volunteers	after	
giving	 written	 informed	 consent.	 The	 study	 was	 approved	 by	 the	 Medical	 Ethical	
Committee	of	the	University	of	Leuven	(Reference	number:	S56976).	
	
Chromatin	immunoprecipitation	(ChIP)	assay	
	
ChIP	 experiments	 have	 been	 performed	 using	 the	megakaryocytic	 CHRF	 cell	 line.	 The	
detailed	protocol,	adapted	from	Pistoni	et	al.,30	 is	reported	 in	Supplemental	methods.	
We	designed	10	amplicons	P1-P10,	(characteristics	and	genomic	location	are	reported	in	
Table	S1)	The	ChIP-qPCR	data	relative	to	histones	are	presented	as	%	input/tot	H3:	2^(-
(CT	Histone	modification	–	CT	10%	input))/2^(-(CT	Total	H3	–	CT	10%	input)).		
	
Electrophoretic	Mobility	Shift	Assays	(EMSAs)		
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Nuclear	 proteins	 were	 extracted	 from	 CHRF-288-11,	 MEG01,	 EA.hy926	 and	 HEK-293	
cells	and	their	total	protein	concentration	was	determined	by	Bradford	analysis.	Single	
stranded	 33	 bp	 5`Biotin-labeled	 oligonucleotides	were	 synthesized	 by	 Integrated	DNA	
Technology	 (Integrated	 DNA	 Technologies,	 Leuven,	 Belgium)	 and	 then	 annealed	 to	
generate	 double	 stranded	 probes.	 Three	 probe	 combinations	 were	 generated	
containing	either	the	A	or	the	G	allele	with	or	without	methylation	at	its	preceding	C,	at	
the	CpG-SNP	position.	Specific	details	on	probes	are	reported	in	Table	S2.		
	
Luciferase	gene-reporter	assay	
	
The	PGL3	promoter	vector	and	assay	reagents	were	bought	from	Promega	Corporation	
(Fitchburg,	WI,	 USA).	 A	 223-bp	 DNA	 fragment	 containing	 the	 CpG-SNP	was	 amplified	
(chr1:156899830-156900052,	 GRCh38/hg38	 Assembly)	 by	 PCR	 with	 DNA	 from	 two	
subjects	homozygous	for	the	rs1204331	A/G	polymorphism	(G/G	and	A/A,	respectively)	
and	inserted	in	a	PGL3	promoter	vector	(further	details	on	protocol	are	reported	in	the	
Supplemental	methods).	The	PGL3	plasmids	and	GFP	control	vector	were	cotransfected	
into	HEK-293	 cells	 using	 Polyplus	 transfection	 kit	 (Polyplus,	 Illkirch,	 France).	 Enhancer	
activity	was	expressed	by	 relative	 light	units	of	 luciferase	normalized	 to	 the	 luciferase	
measured	in	empty	pGL3-promoter	vector.	One-way	ANOVA	was	used	to	determine	the	
significance	 of	 differences	 in	 luciferase	 expression	 among	 PGL3	 promoter,	 with	 a	
significance	level	defined	at	p<0.05.		
	
Human	CD34+	stem	cell	differentiation	in	vitro	
	
Human	CD34+	hematopoietic	stem	cells	(HSCs)	were	separated	by	magnetic	cell	sorting	
from	 buffy	 coats	 isolated	 from	 healthy	 donor	 peripheral	 blood	 (Milteny	 Biotech,	
Auburn,	CA)	using	a	protocol	modified	from4	and	described	in	Supplemental	methods.		
The	 cultured	 CD34+	 cells	 were	 harvested	 on	 days	 0,	 7	 and	 14,	 washed	 in	 Dulbecco	
phosphate-buffered	saline	(PBS)	before	the	cell	pellets	were	either	snap-frozen	in	liquid	
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nitrogen	and	stored	at	-80°C	for	further	DNA	and	RNA	extraction	or	processed	to	detect	
CD34,	 CD41	 and	 PEAR1	 expression	 by	 flow	 cytometry	 using	 APC-labeled	 CD34,	 FITC-
labeled	CD41	(Becton	Dickinson)	and	anti-hPEAR1	PE	(clone:	FAB45278,	R&D	systems).	
PEAR1	 and	 GAPDH	 expression	 analysis	 by	 quantitative	 RT-PCR	 was	 performed	 as	
described	in	the	Supplemental	methods.	
	
DNA	methylation	analysis		
	
CpG-SNP	 methylation	 was	 assessed	 by	 bisulfite-sequencing	 or	 bisulfite	 cloning	 and	
sequencing,	using	primers	reported	in	Table	S3.	
PEAR1	(CGI1,	CGI2	and	intron	1	region)	methylation	was	evaluated	using	the	Sequenom	
EpiTYPER	 MassARRAY	 platform	 as	 described.31,32	 Details	 for	 the	 protocol	 used	 are	
described	in	the	Supplemental	methods.	Statistical	analysis	was	performed	using	One-
way	 ANOVA	 with	 Friedman	 test,	 with	 a	 significance	 level	 of	 p<0.05	 to	 study	 the	
progression	 of	 methylation	 during	 MK	 differentiation	 and	 unpaired	 t-test,	 with	 a	
significance	level	of	p<0.05	to	investigate	differences	between	G-	and	A-allele	carriers.		
Results	
	
Transcriptional	activity	control	by	epigenetic	modification	of	rs12041331		
	
PEAR1	is	encoded	by	23	exons	located	on	chromosome	1q23.1	(Figure	1)	with	two	CpG	
islands	 covering	 1)	 the	 first	 untranslated	 exon	 region	 (CGI1)	 and	 2)	 the	 region	
comprising	exons	8-9	(CGI2),	both	with	a	potential	regulatory	role	 in	the	expression	of	
PEAR1.	 Several	 transcripts	 arise	 from	 the	 PEAR1	 promoter	 but	 only	 2	 of	 them	 are	
translated	 into	 a	 full	 receptor	 (Figure	 1).	 The	G	 to	A	 polymorphic	 variant	 rs12041331	
(CpG-SNP)	 is	 located	 within	 a	 non-coding	 region	 of	 about	 10kb	 that	 links	 the	 first	
untranslated	exon	to	the	transcription	start	site	(TSS)	of	PEAR1,	located	downstream	the	
CpG-SNP	 (Figure	 1).	 We	 examined	 the	 histone	 modification	 profile	 of	 this	 region	
obtained	from	ChIP-seq	data	in	megakaryoblastic	K562	and	HUVEC	endothelial	cell	lines	
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available	 in	ENCODE.	 In	general,	gene	activity	 is	 linked	to	high	 levels	of	H3K4Me3	and	
H3K27Ac.33-37	 Enhancer	 regions	 are	 typically	 enriched	 for	 H3K4Me1	 marking	 while	
poised	 enhancers	 harbor	 H3K4me1	 and	H3K27Me3[12],	 and	 active	 enhancers	 are	 co-
marked	 by	 H3K4Me1	 and	 H3K27Ac.38-40	 From	 this	 first	 analysis,	 the	 PEAR1	 intronic	
region	 where	 the	 CpG-SNP	 is	 located	 shows	 enrichment	 for	 histone	 modifications	
H3K4Me1	and	H3K27Ac,	with	particular	higher	deposition	in	HUVECs	(light	blue	peaks	in	
Figure	 1),	 and	 a	 DNAse	 Hypersensitivity	 I-dependent	 open	 chromatin	 conformation	
(Figure	1).		
PEAR1	 is	mostly	 expressed	 in	megakaryocytes,	 platelets	 and	 endothelial	 cells.1	 To	 be	
able	to	integrate	and	validate	ENCODE	data	relative	to	histone	modifications	within	the	
CpG-SNP	 region,	 we	 have	 used	 4	 different	 hematopoietic	 cell	 lines	 (erythroblastoid	
K562,	myeloid	MEG01	and	megakaryocytic	DAMI	and	CHRF)	to	identify	the	one	with	the	
highest	expression	of	PEAR1.	Via	quantitative	RT-PCR,	we	observed	that	the	CHRF	cells	
express	8	times	higher	PEAR1	levels	compared	to	K562,	while	MEG01	and	DAMI	show	an	
intermediate	PEAR1	expression	(Figure	S1),	CHRF	cells	were,	therefore,	used	to	perform	
a	 series	 of	 Chromatin	 Immunoprecipitation	 (ChIP)	 experiments.	We	have	 designed	 10	
different	amplicons	to	cover	the	full	PEAR1	intron	region,	including	the	specific	CpG-SNP	
position	(amplicons	P5-6)	(Figure	2A).	A	GAPDH	promoter-specific	amplicon	was	used	as	
positive	or	negative	control	to	evaluate	enrichment	of	4	different	histone	modifications:	
H3K27Ac,	H3K4Me3,	H3K27Me3	and	H3K4Me1.	H3K27Ac	and	H3K4Me3	were	strongly	
enriched	at	the	GAPDH	promoter	amplicon,	while	a	mild	enrichment	was	observed	for	
PEAR1	amplicons	P2	and	P3,	indicating	that	the	PEAR1	intron1	region	in	CHRF	cells	does	
not	contain	promoter	activity	(Figure	2B).	On	the	contrary,	H3K4Me1,	a	known	histone	
modification	 often	 associated	 to	 enhancers,	 was	 also	 enriched	 in	 amplicons	 P1-P6,	
including	the	CpG-SNP	region	(P5	and	P6)	over	the	GAPDH	promoter	signal	for	the	same	
histone,	 while	 it	 was	 detectable	 in	 amplicons	 P7	 to	 P10	 (just	 upstream	 to	 the	 ATG	
starting	codon)	in	a	comparable	way	as	the	GAPDH	promoter	amplicon	(Figure	2B).	To	
further	characterize	the	enhancer	features	of	the	PEAR1	intron1	region,	we	analyzed	the	
H3K27Me3	 deposition	 in	 the	 same	 CHRF	 samples.	 H3K27Me3	 in	 combination	 with	
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H3K4Me1	defines	closed	or	poised	enhancers.41	We	found	that	its	enrichment	was	not	
significantly	different	 from	the	signal	 for	 the	GAPDH	promoter	 region,	 thus	suggesting	
that	the	PEAR1	intron1,	including	the	CpG-SNP	region,	contains	a	primed	enhancer	with	
potential	 binding	 sites	 for	 transcription	 factors	 that	 can	 regulate	PEAR1	 expression	 in	
the	megakaryocytic	specific	CHRF	cell	line.	The	CpG	site	generated	by	the	major	G	allele	
of	PEAR1	 CpG-SNP	 is	 a	 unique	event	 in	 a	 region	of	 around	200bp	downstream	 in	 the	
same	 locus,	 representing	 a	 relevant	 functional	 change	 that	 could	 influence	 gene	
regulation.	We	have	genotyped	leukocyte	DNA	from	a	total	of	90	healthy	individuals	for	
the	CpG-SNP,	60	European	Caucasians	and	30	East	or	South	Asians.	 	We	 identified	44	
G/G	(73.3),	16	G/A	(26.7)	in	the	Caucasian	group	and	found	12	G/G	(40.0),	14	G/A	(46.7)	
and	4	A/A	(13.3)	individuals	in	the	Asian	group.	Allelic	frequency	in	both	groups	was	in	
line	with	the	Minor	Allele	Frequency	of	rs12041331	in	Caucasian	European	(MAF	=	0.9)	
and	in	East	and	South	Asians	(MAF	=	0.46	and	0.37,	respectively).	We	next	investigated	
the	 methylation	 status	 of	 the	 CpG-SNP	 in	 5	 G/G,	 3	 G/A	 and	 2	 A/A	 individuals	 via	
bisulfite-cloning	and	sequencing.	This	analysis	revealed	a	fully	methylated	status	of	the	
C	preceding	the	G	in	all	G-allele	carriers	(Figure	S2).	Full	methylation	for	the	C	preceding	
the	G	was	also	observed	in	the	different	cell	lines.	All	this	evidence	indicated	that	the	G	
allele	is	always	characterized	by	a	fully	methylated	C.		
To	evaluate	the	potential	transcriptional	activity	of	the	G	vs.	the	A	allele,	we	have	used	a	
luciferase	gene	reporter	assay	to	investigate	if	a	given	DNA	sequence	is	able	to	produce	
gene	 transcription	 as	 enhancer	 region.	 For	 this	 purpose	 we	 have	 used	 the	 pGL3-
promoter	 vector	 in	which	a	 sequence	of	 about	200bp	 flanking	 the	CpG-SNP	has	been	
inserted.	 In	agreement	with	previously	 reported	 findings,9	 the	G	allele	was	associated	
with	 considerably	 higher	 luciferase	 transcription	 than	 the	 A	 allele	 (Figure	 S3),	
demonstrating	a	sequence-dependent	 role	of	 this	CpG-SNP	 in	driving	differential	gene	
expression.	Even	the	vectors	used	for	the	luciferase-gene	reporter	assay,	after	they	had	
been	purified	from	competent	bacteria,	showed	a	constantly	full	methylation	status	for	
the	G-allele,	 directly	 linking	 this	 specific	 genetic-epigenetic	 combination	 to	 the	 higher	
transcriptional	activity	in	the	reporter	assay.	
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To	investigate	the	influence	of	methylation	on	the	nuclear	protein	binding	properties	for	
G	allele,	we	performed	a	classical	EMSA	using	5`-biotinylated	probes	corresponding	to	
location	 chr1:156899906-156899938	 (GRCh38/hg38	Assembly)	 and	 including	 the	 CpG-
SNP.	 More	 specifically,	 we	 have	 used	 3	 different	 double-stranded	 probes	 containing	
either	the	G	allele	with	or	without	methylation	at	the	C	preceding	the	G	(referred	to	as	
Gmeth	and	G,	 respectively)	or	 the	A	allele,	 and	 incubated	 these	with	nuclear	extracts	
from	 CHRF,	 MEG01,	 EA.hy926,	 but	 also	 HEK-293	 cells.	 In	 all	 conditions,	 the	 Gmeth	
resulted	 in	 significantly	 increased	 recruitment	of	nuclear	proteins	 compared	 to	 the	G-
allele,	non-methylated	at	the	preceding	C,	or	the	A	allele	(Figure	3),	with	different	DNA-
protein	 complexes	 formed	 for	 the	 various	 genotypes	 analyzed	 (Figure	 3).	 Additional	
controls	with	scrambled	5`-biotinylated	probes	confirmed	that	increased	nuclear	protein	
binding	only	occurred	when	methylation	was	 indeed	present	 at	 the	CpG-SNP	position	
and	not	at	another	cytosine	in	the	scrambled	probe	(not	shown).		
The	formation	of	different	DNA-protein	complexes	between	the	Gmeth	versus	A	probes	
are	 suggestive	 for	 genotype-specific	 and	 methylation-dependent	 nuclear	 protein	
binding.	 To	 speculate	 whether	 the	 CpG-SNP	 disrupts	 possible	 transcription	 factor	
binding	sites	(TFBS),	we	have	investigated	the	putative	CpG-SNP	region	(25	bp)	using	the	
PROMO	software	with	the	presence	of	the	G	versus	A-allele.42,43	PROMO	uses	TRANSFAC	
databases	 to	 search	 for	 putative	 TFBS.	 PROMO	 analysis	 generated	 a	 prediction	 of	 at	
least	 10	 different	 interacting	 transcription	 factors	 for	 each	 of	 the	 alleles,	 but	 with	 2	
predicted	to	bind	exclusively	to	the	G	–allele,	 i.e.	ATF3	and	c-Jun,	while	YY1	only	binds	
only	to	the	A-allele	(Figure	3).	However,	this	software	does	not	account	for	the	impact	
of	methylation	status	for	the	G	allele	on	nuclear	protein	binding.		
	
Role	 of	 CpG-SNP	 and	 DNA	 methylation	 in	 primary	 CD34+	 hematopoietic	 stem	 cell	
proliferation	and	differentiation	to	megakaryocytes	
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Our	group	has	previously	reported	a	significant	 increase	of	PEAR1	expression	 in	CD34+	
hematopoietic	stem	cells	(HSC)	during	their	differentiation	into	megakaryocytes	(MK).4	
To	elucidate	whether	increase	in	PEAR1	expression	during	MK	differentiation	would	also	
be	associated	with	the	CpG-SNP,	we	have	isolated	CD34+	cells	from	peripheral	blood	of	
11	 healthy	 donors	 (8	 G/G,	 2	 A/G	 and	 1	 A/A),	 and	 have	 induced	 in	 vitro	 MK	
differentiation	 for	 14	 days.	 Cells	 have	 been	 harvested	 at	 day	 0,	 day	 7	 (proliferation	
phase)	and	day	14	(maturation	phase).	During	this	time	frame,	MK	differentiation	(CD34	
and	 CD41a)	 and	 PEAR1	 expression	were	monitored	 via	 FACS	 analysis	 (Figure	 4A,	 left	
panel).	 The	 analysis	 shows	 that	 CD41a	 expression	 is	 intermediate	 at	 day	 7,	 whereas	
PEAR1	expression	already	reached	maximal	expression	levels	at	this	time	point.	Analysis	
of	 the	 median	 fluorescence	 intensity	 at	 this	 time	 point	 for	 all	 individuals	 revealed	
further	 and	 progressive	 differentiation	 for	 CD41a	 from	 day	 7	 to	 14,	 whereas	 PEAR1	
remained	unchanged	during	MK	maturation	(Figure	4A,	right	panel).	
To	evaluate	a	possible	 influence	of	 the	CpG-SNP	on	MK	progenitors	during	 the	 first	 7	
differentiation	 days,	 we	 performed	 a	 clonogenic	 culture	 assay	 of	 CD34+	 HSC	 isolated	
from	3	G/G,	2	A/G	and	1	A/A	carriers	(all	Asians).	Total	CFU-MK	colonies	were	counted	
in	a	blinded	manner	at	day	8	after	isolation	and	while	the	total	number	of	colonies	was	
not	different	according	to	the	genotype,	we	observed	significant	differences	in	the	size	
of	 single	 MK	 colonies.	 The	 A-allele	 carriers	 had	 significantly	 larger	 CFU-MK	 colonies	
compared	to	G/G	carriers	that	mainly	have	small	MK	colonies	(Figure	4B,	left	panel).	We	
did	not	obtain	enough	cells	 to	study	MK	ploidy	but	genetic	defects	 in	MK	maturation,	
ploidy	and	proplatelet	formation	(e.g.	GATA1,44,45	DIAPH146)	typically	have	enlarged	and	
dense	MK	colonies.	In	addition,	we	have	shown	before	that	human	PEAR1	knock-down	
megakaryocyte	 progenitors	 proliferate	 more	 than	 progenitors	 that	 can	 upregulate	
PEAR1	during	differentiation.4	
Quantitative	 RT-PCR	 (n=4)	 also	 confirmed	 that	 PEAR1	 expression	 increases	 during	
differentiation,	as	reported	before4	(data	not	shown).	To	investigate	whether	the	PEAR1	
expression	 would	 be	 different	 in	 cells	 committed	 towards	 MK	 maturation,	 we	
investigated	 the	 median	 fluorescence	 intensity	 of	 PEAR1	 in	 CD41a	 positive	 cells	
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(selection	 shown	 in	Figure	 S4).	We	were	not	 able	 to	 identify	 significant	differences	 in	
the	CD41a-normalized	PEAR1	expression	between	G/G	and	A-allele	carriers	(Figure	4B,	
right	panel)	at	day	7	or	day	14	of	MK	progenitor	differentiation.		
	
During	HSC	differentiation	to	MKs,	the	C	preceding	the	G	variant	 in	the	G-carriers	was	
constantly	fully	methylated.	To	identify	whether	other	methylation-sensitive	loci	would	
play	 a	 role	 in	PEAR1	 expression,	we	 selected	 3	 other	 regions	within	 the	PEAR1	 locus	
(Figure	 5A)	 and	 performed	methylation	 estimate	measurements	 using	 the	 Sequenom	
EpiTYPER.	 This	 methylation	 analysis	 involves	 both	 CpG	 islands	 (“PCGI1”	 and	 “PCGI2”	 in	
Figure	 5A)	 and	 the	 P3	 intronic	 region	 where	 the	 strongest	 enrichment	 of	 histone	
H3K27Me3	 and	 H3K4Me1	 was	 observed	 in	 previous	 ChIP	 experiments	 (indicated	 as	
“Pintron1”	in	Figure	5A)	for	a	total	of	67	CpG	sites.	Significantly	increasing	methylation	was	
only	observed	during	MK	progenitor	differentiation	for	the	CGI1	region,	that	co-localizes	
with	 the	 first	 untranslated	 exon	 of	 PEAR1	 but	 also	 is	 located	 close	 to	 the	 predicted	
enhancer	 region	 (Figure	 2).	We	 evaluated	 total	methylation	 as	 an	 average	 of	 32	 CpG	
sites	and	observed	that	during	MK	differentiation	it	significantly	increased	from	3±1%	at	
day	0	to	14±4%	at	day	14	(One-way	ANOVA	with	Friedman	test,	p=0.0011)	(Figure	5B).	
Specific	 individual	 CpG-site	 analysis	 showed	 that	 CpG7-8	 and	 CpG19-22	 significantly	
increased	methylation	from	day	0	to	day	7	and	further	mildly	 increased	from	day	7	to	
day	14	 (Figure	5C,	 top	panel).	Pintron1	and	PCGI2	remained	highly	methylated	throughout	
HSC	to	MK	differentiation	(Figure	5B).		
Though	overall	PEAR1	methylation	was	not	different	at	PIntron	and	PCGI2	between	G/G	and	
A-allele	 carriers,	 a	 significantly	 higher	methylation	 for	 the	CpG	 sites	 7-8,	 11-13,	 19-22	
and	31-32	in	the	PCGI1	region	was	observed	for	G/G	carriers	at	the	end	of	differentiation	
day	14	(unpaired	t-test,	p<0.05)	(Figure	5D).		
	
Discussion	
	
PEAR1	 is	 highly	 expressed	 in	 platelets	 and	 megakaryocytes	 and	 participates	 in	 both	
platelet	activation	and	megakaryocyte	progenitor	proliferation.2,4	The	minor	A-allele	of	
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rs12041331	was	found	to	be	associated	with	 lower	PEAR1	expression	 in	platelets9	and	
associations	with	 inter-individual	 variability	 in	 the	 responses	 to	 antiplatelet	 drugs	 has	
been	shown.	A	recent	genome-wide	study	also	associated	rs12566888	(the	only	SNP	in	
high	 linkage	 disequilibrium	 (LD)	 with	 rs12041331	 in	 the	 all	 PEAR1	 gene	 region)	 with	
platelet	 aggregation.	 Despite	 this	 evidence,	 in	 a	 study	 involving	 two	 independent	
populations,	 while	 the	 minor	 A-allele	 was	 still	 linked	 to	 lower	 platelet	 function	 on	
aspirin,	it	was	also	found	to	be	a	risk	factor	for	cardiovascular	events.14	All	the	evidence	
produced	 together	 with	 this	 apparently	 divergent	 result	 fostered	 our	 present	
investigations	 focusing	 on	 the	 molecular	 mechanisms	 by	 which	 this	 variant	 would	
modulate	 PEAR1	 expression.	We	 hypothesized	 that	 such	 a	 mechanism	 of	 fine-tuning	
expression,	able	to	interfere	with	residual	platelet	activation	variability,	as	shown	in	the	
different	 epidemiological	 studies,	 could	 be	 mediated	 by	 a	 combination	 of	 genetic	
predisposition	and	epigenetic	mechanisms.		
PEAR1	 variants	 associated	with	 platelet	 function	 and	 individual	 variability	 are	 located	
both	 in	 coding	 and	 in	 non-coding	 regions	 of	 the	 PEAR1	 gene	 and	 4	 (rs2768759,	
rs12041331,	 rs11264579	 and	 rs3737224)	 out	 of	 8	 are	 CpG-SNPs.	 Three	 of	 these	 CpG-
SNPs	are	positioned	either	upstream	the	CGI1	 (rs2768759)	or	 in	 intron1	of	 the	PEAR1	
gene	(rs12041331	and	rs11264579).	The	only	non	CpG-SNP	present	in	the	same	region	
(rs12566888)	is	in	high	LD	with	rs12041331.		
Association	 studies	between	CpG-SNPs	and	certain	phenotypes	are	 increasing,23-29	but	
the	molecular	characterization	of	their	mechanism	of	action	still	remains	a	challenge.		
Most	of	the	CpG-SNPs	functionally	characterized	are	located	in	the	5’-UTR	or	promoter	
regions,48-51	while	PEAR1	rs12041331	is	located	in	a	non-coding	intronic	region,	yet	with	
specific	 enhancer	 features.	 Independently	 of	 their	 genomic	 location,	 CpG-SNPs	
collectively	appear	to	act	by	impeding	or	facilitating	the	binding	of	specific	factors	that	
define	their	functional	role	 in	gene	expression.	 In	the	case	of	rs12041331,	the	 latter	 is	
suggested	 by	 the	 enhanced	 DNA-protein	 binding	 for	 the	 major	 G	 allele,	 which	 we	
observed	 in	 EMSA	 coupled	 to	 DNA	 methylation.	 Our	 study	 is	 in	 line	 with	 previous	
reports	on	the	impact	of	rs12041331	on	platelet9	and	endothelial	cell20	function	and	it	
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adds	epigenetic	and	allele-specific	methylation	as	new	regulatory	mechanism	for	PEAR1	
regulation.		
Three	different	transcription	factors	are	predicted	to	bind	to	the	G-	or	the	A-allele:	ATF3	
and	c-Jun	and	YY1,	respectively.	Even	if	the	prediction	of	these	factors	does	not	take	in	
account	the	influence	of	DNA	methylation,	it	is	interesting	to	know	that	both	YY1	and	c-
Jun	have	been	found	to	be	highly	enriched	in	enhancer	regions	in	a	number	of	cell	lines	
including	HUVECs.47	In	addition	to	that,	a	recent	study	defines	the	binding	profile	of	TFs	
to	the	DNA	Methyl	Transferases	(DNMTs),	the	enzymes	responsible	for	the	maintenance	
or	 the	 de	 novo	 deposition	 of	 DNA	methylation.52	 ATF3,	 c-Jun	 and	 YY1	 have	 all	 been	
found	 to	 interact	 with	 DNMT3L,	 the	 enzyme	 that	 participates	 in	 de	 novo	 DNA	
methylation	by	 interacting	with	DNMT3A	and	DNMT3B.	This	 interaction	could	be	both	
activating	 or	 inhibiting	 the	 action	 of	 DNMT3L	 representing	 a	 possible	 mechanism	 by	
which	the	G-methylated	allele	contributes	to	the	CGI1	de	novo	methylation	during	MK	
differentiation	(Figure	6).		
	
Methylation	 at	 rs12041331	 is	 associated	with	 a	 higher	 PEAR1	 expression	 in	 platelets9	
and	 differential	 function	 in	 both	 platelets9-11,14,16-18	 and	 endothelial	 cells.20	 While	 an	
inverse	correlation	between	DNA	methylation	and	gene	expression	is	very	well	known,	
the	opposite	is	not	yet	well	understood	although	reported	in	some	large-scale	studies53	
and	highly	 dependent	 on	 the	 genomic	 context.54-56	 To	better	 understand	 this	 unusual	
relation	between	DNA	methylation	and	gene	expression,	we	have	studied	PEAR1	DNA	
methylation,	during	early	and	late	megakaryopoiesis.	We	found	that	parallel	progressive	
elevation	 of	 PEAR1	 CGI1	 methylation	 and	 PEAR1	 expression	 occurs	 in	 early	
differentiation.	At	the	same	time,	we	also	observed	that	rs12041331	was	constitutively	
methylated	 throughout	 differentiation.	 CpG-SNP	 allele-specific	 methylation	 occurs	 at	
the	same	time	also	at	the	CGI1	region	of	the	gene,	where	A-allele	carriers	present	with	
significantly	lower	methylated	CpG	sites.	Taken	together	with	the	different	methylation	
at	 CGI1,	 rs12041331	 contributes	 to	 drive	 and	 finetune	 PEAR1	 expression	 in	 platelets.	
This	 interpretation	 is	 in	 line	 with	 the	 reported	 platelet	 PEAR1	 protein	 differences	
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between	 individuals	 with	 the	 two	 genotypes9	 as	 well	 as	 with	 the	 luciferase	 gene-
reporter	 assay,	 which	 measured	 the	 isolated	 effect	 of	 the	 methylated	 G	 allele	 for	
rs12041331.	 Although	 we	 could	 not	 detect	 significant	 differences	 in	 MK	 PEAR1	
expression	 at	 the	 end	 of	 differentiation,	we	 hypothesize	 that	 its	 expression	might	 be	
more	 important	 for	proliferation	at	 the	 very	early	 stages	of	differentiation,	where	we	
observed	 differences	 in	 the	 size	 of	 the	 CFU-MK	 between	 A-allele	 carriers	 and	 GG	
homozygotes	 (Figure	 4B,	 left	 panel).	 In	 fact	 PEAR1	 reaches	maximal	 expression	 levels	
already	at	day	7	of	differentiation	suggesting	that	a	still	earlier	time	point	might	better	
reveal	differences	in	PEAR1	expression	between	the	GG	and	A-allele	carriers.	We	could	
not	include	such	analysis	in	our	present	study,	because	of	the	limited	sample	availability	
(comprising	 a	 single	 AA	 carrier	 only)	 and	 to	 the	 necessity	 to	 already	 determine	
membrane	protein	expression	studies	on	these	samples	(FACS),	CFU-MK	colony	assays	
and	 DNA	methylation	 studies.	We	 did	 analyze	 PEAR1	 expression	 as	 a	 function	 of	 the	
Forward	 Scatter,	 an	 index	 of	 cellular	 size,	 and	 hence,	 indirectly	 of	 megakaryocyte	
maturation,	during	which	process	the	higher	ploidy	results	in	larger	cell	masses.		
The	CpG	sites	of	the	CGI1	regions	that	undergo	the	most	significant	methylation	changes	
identified	 in	 the	MK	progenitor-specific	 analysis,	 reside	within	predicted	CTCF	binding	
sites.	CTCF	is	an	important	player	regulating	complex	processes	including	transcription,	
imprinting,	long-range	chromatin	interactions	and	subnuclear	localization	in	health	and	
disease.	Its	binding	has	been	shown	to	be	highly	influenced	by	DNA	methylation	both	in	
vitro	and	 in	vivo,	and,	in	combination	with	other	regulatory	mechanisms,	drives	spatial	
and	temporal-dependent	gene	expression.	ENCODE	CTCF	annotations	 for	HUVECs	that	
express	high	 levels	of	PEAR1,	show	binding	of	CTCF	at	the	CGI1	region,	and	moreover,	
specifically	located	in	that	region	investigated	by	us	in	the	methylation	study	(Figure	1).	
At	the	same	region,	also	specific	active	enhancer-interacting	promoter	histone	marks47	
are	 present	 (H3K27Ac	 and	 H3K4Me3),	 while	 H3K4Me1,	 typically	 defining	 enhancers	
(such	 as	 the	 rs12031441	 region),	 is	 not	 comparably	 enriched.	 This	 region	 is	 highly	
conserved	 across	 vertebrates	 (Figure	 1,	 last	 track)	 suggesting	 its	 possible	 relevance	
during	 evolution.	 CTCF	 binding	 may	 play	 an	 important	 role	 in	 mediating	 interactions	
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between	 the	CGI1	 region	and	 the	gene	TSS,	 located	approximately	10kb	downstream.	
CTCF	 binding	 depends	 on	 higher	 CpG	 content57	 and	 DNA	 methylation	 restricting	
enhancer-mediated	 transcriptional	 inductions	 or	 working	 as	 a	 chromatin	 barrier	
separating	 active	 and	 repressive	 domains	 at	 gene	 promoters	 or	 enhancers.58	 CTCF	
binding	at	PEAR1	CGI1	would	then	be	prevented	by	elevated	methylation,	allowing	the	
downstream	locus	to	act	as	an	active	enhancer	in	the	PEAR1	transcription	in	G-carriers.	
This	 model	 is	 in	 line	 with	 the	 higher	 G-allele	 dependent	 expression	 and	methylation	
observed.	 At	 the	 same	 time,	 PEAR1	 CGI1	 could	 be	 the	 enhancer	 of	 more	 distant	
promoters	along	chromosome	1	influencing	transcription	of	other	genes59.		
In	 conclusion,	 we	 have	 mechanistically	 characterized	 the	 role	 of	 the	 CpG-SNP	
rs12041331	as	genetic	predisposition	that	capacitates	PEAR1	enhancer	activity	through	
allele-specific	 methylation.	Future	 studies	 are	 needed	 to	 investigate	 whether	 this	
mechanism	of	gene	regulation	is	highly	specific	for	PEAR1	exclusively	or	also	applies	to	
more	platelet	function-	or	megakaryopoiesis-related	genes.	
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Legends	to	figures	
	
Figure	1.	PEAR1	gene	structure	(chr1:156893731-156916434,	GRCh38/hg38	Assembly).		
Exons	are	indicated	by	full	blue	boxes.	The	ATG	codon	is	indicated	at	exon1.	The	major	
PEAR1	 transcript	 (ENST00000292357),	 translated	 into	 the	 full	 PEAR1	 receptor,	 is	
indicated	as	“X”	(in	magenta).	Two	CpG	islands	are	located	in	the	gene	(CGI1	and	CGI2,	
depicted	as	green	boxes	on	the	 left	and	right	side,	respectively.	Location	chromosome	
1:156892430-156893919	 and	 156907978-156908857,	 GRCh38/hg38	 Assembly).	
Rs12041331	(chr1:156899922,	GRCh38/hg38	Assembly)	 is	 indicated	in	red.	CpG	islands	
are	 defined	 based	 on	 the	 formula	 described	 by	 Gardiner-Garden).60	 	 H3K4Me1,	
H3K4Me3	and	H3K27Ac	profiles	 in	HUVEC	and	K562	cell	 lines	are	displayed	as	colored	
overlayed	histograms	(light	blue	for	HUVEC	and	purple	for	K562)	in	“auto-scale	to	data	
view”	 mode	 that	 takes	 the	 highest	 signal	 in	 the	 selected	 region	 as	 the	 100%	 of	 the	
intensity	and	display	all	other	signals	accordingly	(data	produced	by	the	Bernstein	Lab	at	
the	 Broad	 Institute	 and	 the	 UCSC	 and	 part	 of	 the	 ENCODE	 database).	 DNase	
Hypersensitivity	1	regions	are	displayed	as	gray	to	black	boxes	(from	less	to	more	open	
chromatin	 conformation).	 CTCF	 ChIP-seq	 data	 from	 HUVECs	 and	 K562	 cell	 lines	 are	
depicted	 as	 colored	histograms	 in	 full	 visualization	 and	 are	 normalized	 for	 IgG	 signals	
(data	produced	by	ENCODE).	PEAR1	conservation	across	vertebrates	is	displayed	as	blue	
histograms	 at	 the	 bottom	 of	 the	 figure	 using	 the	 Vertebrate	 Multiz	 Alignment	 &	
Conservation	(100	Species)	UCSC	track.	“PCGI1”	(also	depicted	as	black	box)	refers	to	the	
region	we	analyzed	 for	DNA	methylation	estimates	 in	CD34+	hematopoietic	 stem	cells	
into	 megakaryocyte	 precursors	 and	 better	 described	 in	 figure	 5.	 A	 yellow	 box	
(discontinue	 line)	 highlights	 the	 PCGI1	 region	 that	 co-localizes	 with	 CTCF	 binding	 in	
HUVECs	 and	 shows	 conservation	 across	 different	 vertebrates.	 Exons	 15	 and	 16	 are	
indicated	 in	 brown	 and	 indicate	 the	 region	 used	 for	 real-time	 q-PCR	 quantification	 of	
PEAR1	expression	in	the	present	study. 
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Figure	 2.	 Histone	 modifications	 profiling	 of	 PEAR1	 intron1	 region	 via	 Chromatin	
Immuno-precipitation	(ChIP)		
(A)	Graphical	representation	of	PEAR1	intron1	region.	Primers	were	randomly	selected	
to	 cover	 the	 full	 intronic	 region,	 including	 rs12041331	 (amplicons	 P5	 and	 P6	 in	
correspondence	of	rs12041331	indicated	above	the	gene	line)	and	are	depicted	as	black	
boxes.	 (B)	 Levels	 of	 CHRF	 PEAR1	 intron1	 (P1-P10)	 and	 GAPDH	 amplicons	
immunoprecipitated	 using	 H3K27me3,	 H3K4me3,	 H3K27ac	 and	 H3K4me1	 antibodies	
measured	 following	 polymerase	 chain	 reaction	 (PCR)	 amplification	 of	 DNA	 fragments.	
Signals	from	IgG	control	antibody	used	for	each	ChIP	were	subtracted	from	each	of	the	
histone	modification	IPs	signals	and	the	fold	enrichment	ratios	of	ChIP	enriched	versus	
total	input	DNA	were	represented	(n=4	for	each	histone,	average	±	SEM).	
	
Figure	3.	Transcriptional	activity	of	rs12041331	and	enhancing	role	of	methylation	at	
the	G	allele.		
EMSA	 analysis	 to	 characterize	 the	 methylated	 G-allele	 vs.	 the	 G-allele	 and	 A-allele	
binding	 properties	 to	 nuclear	 proteins.	 EMSA	 were	 performed	 using	 5`biotinylated	
probes	corresponding	to	location	chr1:156869698-156869731	(GRCh38/hg38	Assembly)	
and	 including	rs12041331.	 (A,C)	Biotinylated	double	stranded	probes	containing	the	G	
allele	with	(‘Gmeth’)	or	without	(‘G’)	methylation,	or	the	A	allele	(‘A’)	were	incubated	in	
the	presence	of	a	10X	amount	of	cold	probe	(lanes	1-3),	or	alone	with	a	fixed	amount	of	
nuclear	 extract	 from	 CHRF	 (A)	 or	MEG01,	 EA.hy926	 or	 HEK-293	 cells	 (C).	 (lanes	 4-6).	
Lanes	 7-9	 show	 unbound	 biotinylated	 probes	 in	 all	 cases.	 Methylation	 significantly	
enhanced	binding	of	 the	probe	 to	nuclear	extract	proteins	as	 shown	by	 the	 increased	
normalized	 intensity	 of	 the	 signal	 in	 lane	 4	 vs.	 that	 in	 lane	 5	 and	 6,	 quantified	 for	 3	
replicates	of	CHRF	 cells	 (A,	mean	±	 SD)	 and	 for	 the	other	3	 cell	 lines	 investigated	 (C),	
expressed	as	lane	Integrated	Density.	(D)	PROMO	based	putative	binding	sites	search	for	
CpG-SNP	region	(25bp).	The	G-allele	(top	panel)	produced	specific	binding	prediction	for	
c-Jun	(indicated	as	number	7)	and	ATF3	(indicated	as	number	8),	while	for	the	A-allele	
(bottom	panel)	YY1	(indicated	as	number	3)	is	predicted	to	bind	the	SNP	site.	 
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Figure	 4.	 Influence	 of	 Rs12041331	 on	 MK	 progenitor	 proliferation	 and	 PEAR1	
expression	during	megakaryocyte	differentiation	
(A)	Left	panel:	histogram	for	CD41a	and	PEAR1	during	differentiation	of	CD34+	cells	from	
day	0	to	day	14,	as	indicated.	Right	panel:	CD34,	CD41a	and	PEAR1	expression	measured	
by	FACS	analysis	and	expressed	as	Mean	Fluorescence	Intensity	during	differentiation	of	
CD34+	cells	into	MK	precursors	harvested	at	day	0	(D0),	day	7	(D7)	and	day	14	(D14).	(B)	
Left	panel:	Number	of	CFU-MK,	defined	as	small	(3-20	cells),	medium	(20-80	cells)	and	
large	(>80	cells)	colonies,	counted	in	a	blind	fashion	at	day	8	after	differentiation	in	GG	
(n=3)	 vs.	AG+AA	 (n=3)	 individuals.	 *p<0.05,	 multiple	 unpaired	 t-test	 with	 post	 Holm-
SIdak	 for	multiple	 comparisons.	 Right	 panel:	GG	 (n=2)	 vs.	AG+AA	 (n=3)	 PEAR1/CD41a	
ratios	measured	on	CD41a	positive	events	at	day	7	of	differentiation.	SP1,	SP2,	SP3	are	
CD41a	positive	subpopulations	defined	by	marker	positivity	and	size	 (Forward	Scatter,	
FSC)	as	defined	in	figure	S4.	
	
Figure	 5.	 Increased	 PEAR1	 expression	 during	 megakaryopoiesis	 parallels	 DNA	
methylation	enrichment	at	CGI1.	
(A)	 Schematic	 representation	 of	 PEAR1	 regions	 investigated	 in	 the	methylation	 study	
indicated	 as	 black	 vertical	 boxes	 (‘PCGI1’	 in	 CpG-island	 1	 (CGI1),	 ‘Pintron1’	 in	 intron1	 of	
PEAR1,	 ‘rs12041331’,	 ‘PCGI2’	 in	 CpG-island	 2	 (CGI2)).	 (B)	 Sequenom	 methylation	
estimates	(%	average)	for	PCGI1,	Pintron1	and	PCGI2	(bar	representation,	average+/-SD,	n=8).	
(C)	 Single	 CpG	 (dot	 line	 representation),	 during	 differentiation	 of	 CD34+	 cells	 into	MK	
precursors	harvested	at	day	0	(D0),	day	7	(D7)	and	day	14	(D14)	and	(D)	of	GG(n=5)	vs.	
AG+AA(n=3)	methylation	at	day	14.	*p<0.05	one-way	ANOVA.	
	
Figure	 6.	 Epigenetic-dependent	 regulatory	 mechanism	 of	 rs12041331	 in	 PEAR1	
expression	
The	major	G-allele	of	 the	CpG-SNP,	 introduces	a	CpG-site	 in	 the	enhancer	 region	 that	
binds	with	higher	affinity	to	several	nuclear	proteins	than	the	A	allele.	At	the	same	time,	
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the	G-methylated	allele,	marks	higher	methylation	at	CGI1,	the	CpG	island	located	at	the	
UTR	 region	 of	 PEAR1	 that	 contains	 several	 binding	 sites	 for	 CTCF,	 important	 for	
chromosome	looping	and	architecture.	When	higher	methylation	is	present,	CTCF	binds	
with	lower	affinity	to	the	CGI1	region,	liberating	the	enhancer	activity	of	intron	1	where	
the	CpG-SNP	 is	also	 located.	On	 the	contrary,	 lower	methylation	at	CGI1	 is	associated	
with	the	minor	A-allele	of	the	CpG-SNP,	reinforcing	CTCF	binding	and	partially	inhibiting	
gene	 expression.	 This	 model	 advances	 a	 positive	 effect	 of	 methylation	 on	 gene	
expression,	 and	 is	 in	 accordance	with	 the	association	between	 increasing	methylation	
and	PEAR1	expression	during	early	MK	progenitor	development.	
	
	
			
		






